| Recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T- NCT07137416 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gyn NCT07226102 | City of Hope Medical Center | N/A |
| Not Yet Recruiting | Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial NCT07474090 | Wake Forest University Health Sciences | N/A |
| Not Yet Recruiting | Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer NCT05874297 | Fred Hutchinson Cancer Center | N/A |
| Suspended | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer NCT07136493 | City of Hope Medical Center | N/A |
| Recruiting | A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning t NCT07443943 | University of Michigan Rogel Cancer Center | Phase 2 |
| Not Yet Recruiting | Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Mi NCT07191717 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Not Yet Recruiting | Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial NCT05379153 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Not Yet Recruiting | Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor R NCT05741164 | Emory University | Phase 2 |
| Not Yet Recruiting | Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and NCT07460752 | Mayo Clinic | Phase 2 |
| Recruiting | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Loc NCT06434064 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, NCT07158021 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative B NCT06324240 | Emory University | Phase 1 |
| Recruiting | An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Posit NCT06999798 | Mayo Clinic | Phase 1 |
| Recruiting | Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III NCT06954831 | City of Hope Medical Center | Phase 2 |
| Recruiting | The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patient NCT07341503 | Ohio State University Comprehensive Cancer Center | — |
| Withdrawn | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Tre NCT06590558 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss NCT07044310 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Brea NCT06630325 | OHSU Knight Cancer Institute | Phase 2 |
| Active Not Recruiting | Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Surviv NCT06643455 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Bre NCT06635980 | Mayo Clinic | Phase 2 |
| Recruiting | Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial NCT05930483 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | Integrative Approaches for Cancer Survivorship (IACS3) NCT06633926 | University of California, San Francisco | N/A |
| Withdrawn | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negat NCT05539365 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemother NCT06763328 | City of Hope Medical Center | Phase 3 |
| Recruiting | Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women Wi NCT06534125 | Emory University | N/A |
| Terminated | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VEN NCT06617455 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast C NCT06582615 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors NCT06392789 | University of Washington | N/A |
| Recruiting | Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 NCT06042569 | City of Hope Medical Center | Phase 2 |
| Recruiting | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors NCT06113016 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negat NCT06179303 | University of Washington | Phase 2 |
| Recruiting | Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy NCT06401889 | Mayo Clinic | — |
| Terminated | Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Brea NCT06238986 | Mayo Clinic | — |
| Completed | An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutri NCT06193070 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclopho NCT06058377 | National Cancer Institute (NCI) | Phase 3 |
| Withdrawn | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial NCT05967286 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) NCT05673200 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial NCT06016725 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Ad NCT05372640 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) NCT06106282 | Mayo Clinic | — |
| Recruiting | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Respo NCT05812807 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Recruiting | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard NCT05422794 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer NCT05710328 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study NCT05568472 | SWOG Cancer Research Network | N/A |
| Recruiting | Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors NCT05595499 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Suspended | Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Ca NCT05547347 | Mayo Clinic | — |
| Recruiting | Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV NCT05417308 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cance NCT05677802 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer NCT05455658 | University of Washington | Phase 2 |
| Completed | Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivo NCT05674578 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Can NCT04593277 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Sta NCT05368428 | Emory University | N/A |
| Recruiting | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negati NCT05464810 | Emory University | EARLY_Phase 1 |
| Terminated | Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy NCT04835597 | M.D. Anderson Cancer Center | — |
| Recruiting | Neoadjuvant Breast Cancer Time Restricted Eating NCT05327608 | Thomas Jefferson University | N/A |
| Completed | Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer NCT05945290 | Mayo Clinic | — |
| Withdrawn | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Ca NCT05244434 | City of Hope Medical Center | N/A |
| Withdrawn | Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors NCT04560439 | City of Hope Medical Center | N/A |
| Recruiting | Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors NCT05452681 | University of Alabama at Birmingham | N/A |
| Recruiting | A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment NCT05243056 | University of Alabama at Birmingham | N/A |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for NCT04329065 | University of Washington | Phase 2 |
| Recruiting | Breast Cancer Survivorship Biorepository NCT05786664 | University of Southern California | — |
| Recruiting | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer NCT05319873 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Withdrawn | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV T NCT05177796 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain NCT05412953 | Mayo Clinic | N/A |
| Recruiting | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer NCT05183828 | University of Washington | Phase 4 |
| Recruiting | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors NCT07259304 | University of Southern California | — |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Completed | An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors NCT05012176 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer NCT05086731 | Emory University | N/A |
| Active Not Recruiting | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448 | University of Washington | Phase 1 |
| Completed | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel NCT04862585 | Ohio State University Comprehensive Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stag NCT04754412 | M.D. Anderson Cancer Center | N/A |
| Completed | Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer NCT04857697 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Sur NCT04906200 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Bre NCT05928325 | M.D. Anderson Cancer Center | N/A |
| Terminated | Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology T NCT04862195 | Blue Note Therapeutics | N/A |
| Completed | Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer NCT05071677 | M.D. Anderson Cancer Center | — |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients NCT04705025 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors NCT04999826 | Mayo Clinic | — |
| Withdrawn | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520 | Pamela Munster | Phase 1 |
| Active Not Recruiting | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Br NCT04457596 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer NCT04345913 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions NCT04549571 | Alliance for Clinical Trials in Oncology | N/A |
| Active Not Recruiting | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiv NCT04379570 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Terminated | Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation The NCT04927559 | University of Southern California | — |
| Completed | Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer NCT04205903 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Nipple Aspirate Fluid in Detecting Breast Cancer NCT03715959 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | SHAPE Neoadjuvant Chemotherapy Response NCT04715958 | Kibo Nam | Phase 2 / Phase 3 |
| Active Not Recruiting | Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer NCT05025059 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Withdrawn | Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal NCT04205071 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Bre NCT04535323 | Mayo Clinic | Phase 1 |
| Terminated | Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients Wit NCT04249622 | Mayo Clinic | Phase 2 |
| Terminated | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer NCT04139993 | Mayo Clinic | Phase 1 |
| Completed | Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer NCT04693338 | Mayo Clinic | Phase 1 |
| Recruiting | Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer NCT04517838 | Mayo Clinic | — |
| Recruiting | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Ca NCT04090567 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients NCT04443413 | Mayo Clinic | Phase 3 |
| Terminated | Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and H NCT04876378 | University of California, San Francisco | — |
| Completed | Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer NCT04294225 | Mayo Clinic | Phase 2 |
| Completed | Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the T NCT04716920 | Thomas Jefferson University | N/A |
| Completed | Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Act NCT04200482 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer NCT03554044 | University of California, San Francisco | Phase 1 |
| Terminated | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With NCT04216472 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer NCT04249167 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Ca NCT03979508 | Mayo Clinic | Phase 2 |
| Terminated | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Patho NCT03872388 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Ca NCT03941730 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer NCT04001829 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Completed | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Can NCT03207529 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer NCT03939481 | SWOG Cancer Research Network | — |
| Active Not Recruiting | Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer NCT04678414 | M.D. Anderson Cancer Center | — |
| Terminated | Exercise and Nutrition Education in Improving Physical Function and Quality of Life in Older Breast Cancer Sur NCT03751449 | Roswell Park Cancer Institute | N/A |
| Completed | Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors NCT04454086 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors NCT03725436 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | EXERCISING TOGETHER for Couples Coping With Cancer NCT03630354 | OHSU Knight Cancer Institute | N/A |
| Active Not Recruiting | Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With L NCT03786354 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Recep NCT04086875 | Thomas Jefferson University | N/A |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Can NCT03666819 | Mayo Clinic | Phase 2 |
| Completed | Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Posi NCT03774472 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inf NCT03941756 | M.D. Anderson Cancer Center | N/A |
| Completed | Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Can NCT03505671 | Wake Forest University Health Sciences | N/A |
| Completed | M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer NCT03620201 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer NCT03505736 | Wake Forest University Health Sciences | — |
| Completed | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer NCT03518242 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors NCT03523195 | Fred Hutchinson Cancer Center | N/A |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast NCT03179904 | Mayo Clinic | Phase 2 |
| Completed | Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative NCT03132467 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer NCT03106077 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With N NCT02918474 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Canc NCT02849496 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant NCT05049746 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT02453620 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Can NCT02115282 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer NCT01334021 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer NCT01149083 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer NCT00507923 | M.D. Anderson Cancer Center | N/A |